Clinical Trials
19 trialsNCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT05311176 2025-05-11
nextHERIZON
Imugene Limited
Phase 2 Terminated
NCT05207722 2024-12-12
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Celularity Incorporated
Phase 1/2 Terminated
NCT04508140 2024-11-29
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Highlight Therapeutics
Phase 2 Terminated
NCT03809624 2024-10-23
PDL1x41BB
Inhibrx Biosciences, Inc
Phase 1 Terminated
NCT03621982 2024-06-13
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT04187872 2023-12-27
TORCH
University of Florida
Phase 1 Terminated
NCT03019588 2023-03-30
MK-3475-063
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT04510285 2023-02-01
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02757391 2020-10-30
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02346955 2020-08-27
MK-6018-001
KitovPharma
Phase 1 Terminated
NCT03511222 2020-07-29
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
Phase 1 Terminated
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT03122548 2019-04-04
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Aduro Biotech, Inc.
Phase 2 Terminated